Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report.

Ciccullo A, Baldin G, Lombardi F, Borghetti A, Di Giambenedetto S.

AIDS Res Hum Retroviruses. 2020 Feb 6. doi: 10.1089/AID.2019.0270. [Epub ahead of print] No abstract available.

PMID:
31931591
2.

Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.

Baldin G, Ciccullo A, Rusconi S, Madeddu G, Sterrantino G, Freedman A, Giacometti A, Celani L, Latini A, Rossetti B, Cossu MV, Giacomelli A, Lagi F, Capetti A, Di Giambenedetto S.

Infez Med. 2019 Dec 1;27(4):410-414.

3.

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).

Ciccullo A, Baldin G, Capetti A, Borghi V, Sterrantino G, Latini A, Madeddu G, Celani L, Vignale F, Rossetti B, Dusina A, Cossu MV, Restelli S, Gennari W, Lagi F, Giacomelli A, Colafigli M, Brescini L, Borghetti A, Mussini C, Rusconi S, Di Giambenedetto S.

BMJ Open. 2019 Dec 2;9(12):e029960. doi: 10.1136/bmjopen-2019-029960.

4.

Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience.

Colafigli M, Ciccullo A, Borghetti A, Fanti I, Melis F, Modica S, Uccella I, Bonadies A, Ferraresi V, Anzalone E, Pennica A, Migliano E, Rossetti B, Madeddu G, Cauda R, Cristaudo A, Di Giambenedetto S, Latini A.

J Clin Med. 2019 Nov 23;8(12). pii: E2062. doi: 10.3390/jcm8122062.

5.

No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.

Giacomelli A, Lai A, Franzetti M, Maggiolo F, Di Giambenedetto S, Borghi V, Francisci D, Magnani G, Pecorari M, Monno L, Vicenti I, Lepore L, Lombardi F, Paolucci S, Rusconi S; ARCA collaborative group.

Antiviral Res. 2019 Dec;172:104635. doi: 10.1016/j.antiviral.2019.104635. Epub 2019 Oct 17.

6.

Cognitive impairment and cardiovascular disease related to alexithymia in a well-controlled HIV-infected population.

Ciccarelli N, Baldonero E, Milanini B, Fabbiani M, Cauda R, Di Giambenedetto S, Silveri MC.

Infez Med. 2019 Sep 1;27(3):274-282.

7.

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.

Baldin G, Ciccullo A, Rusconi S, Capetti A, Sterrantino G, Colafigli M, d'Ettorre G, Giacometti A, Cossu MV, Borghetti A, Gennari W, Mussini C, Borghi V, Di Giambenedetto S.

Int J Antimicrob Agents. 2019 Dec;54(6):728-734. doi: 10.1016/j.ijantimicag.2019.09.002. Epub 2019 Sep 12.

8.

Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients.

Lombardi F, Belmonti S, Borghetti A, Ciccullo A, Baldin G, Cauda R, Fabbiani M, Di Giambenedetto S.

HIV Res Clin Pract. 2019 Sep 3:1-7. doi: 10.1080/25787489.2019.1653512. [Epub ahead of print]

PMID:
31478469
9.

Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.

Ciccullo A, Baldin G, Cossu MV, Passerini M, Borghetti A, Capetti A, Di Giambenedetto S.

AIDS Res Hum Retroviruses. 2020 Jan;36(1):4-5. doi: 10.1089/AID.2019.0147. Epub 2019 Sep 30. No abstract available.

PMID:
31476877
10.

'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice.

Emiliozzi A, Ciccullo A, Borghetti A, Picarelli C, Farinacci D, Baldin G, Di Giambenedetto S.

HIV Med. 2020 Feb;21(2):e1-e2. doi: 10.1111/hiv.12783. Epub 2019 Jul 23. No abstract available.

PMID:
31338932
11.

Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study.

Rossetti B, Baldin G, Sterrantino G, Rusconi S, De Vito A, Giacometti A, Gagliardini R, Colafigli M, Capetti A, d'Ettorre G, Celani L, Lagi F, Ciccullo A, De Luca A, Di Giambenedetto S, Madeddu G.

Antiviral Res. 2019 Sep;169:104552. doi: 10.1016/j.antiviral.2019.104552. Epub 2019 Jul 5.

PMID:
31283942
12.

Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients.

Fabbiani M, Ciccarelli N, Castelli V, Soria A, Borghetti A, Colella E, Moschese D, Valsecchi M, Emiliozzi A, Gori A, De Luca A, Bandera A, Di Giambenedetto S.

J Neurovirol. 2019 Dec;25(6):866-873. doi: 10.1007/s13365-019-00780-9. Epub 2019 Jul 7.

PMID:
31281946
13.

Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure.

Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, Lombardi F, Emiliozzi A, Belmonti S, Antinori A, Cauda R, Di Giambenedetto S.

HIV Med. 2019 Oct;20(9):624-627. doi: 10.1111/hiv.12759. Epub 2019 Jun 25.

PMID:
31240860
14.

Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.

Lagi F, Baldin G, Colafigli M, Capetti A, Madeddu G, Kiros ST, Di Giambenedetto S, Sterrantino G.

Int J Antimicrob Agents. 2019 Oct;54(4):487-490. doi: 10.1016/j.ijantimicag.2019.06.003. Epub 2019 Jun 11.

PMID:
31195121
15.

Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice.

Emiliozzi A, Ciccullo A, Baldin G, Moschese D, Dusina A, Borghetti A, Di Giambenedetto S.

J Antimicrob Chemother. 2019 Aug 1;74(8):2470-2472. doi: 10.1093/jac/dkz205. No abstract available.

PMID:
31081023
16.

Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC.

Lai A, Simonetti FR, Brindicci G, Bergna A, Di Giambenedetto S, Sterrantino G, Mussini C, Menzo S, Bagnarelli P, Zazzi M, Angarano G, Galli M, Monno L, Balotta C.

Front Microbiol. 2019 Apr 12;10:769. doi: 10.3389/fmicb.2019.00769. eCollection 2019.

17.

Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.

Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group.

Antivir Ther. 2019;24(5):321-331. doi: 10.3851/IMP3309.

18.

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.

Castagna A, Rusconi S, Gulminetti R, Bonora S, Mazzola G, Quiros-Roldan ME, De Socio GV, Ladisa N, Carosella S, Cattelan A, Di Giambenedetto S, Mena M, Poli A, Galli L, Riva A; DAU Study Group.

AIDS. 2019 Jun 1;33(7):1256-1260. doi: 10.1097/QAD.0000000000002188.

PMID:
30870194
19.

Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016.

Bellino S, Borghetti A, Lombardi F, Camoni L, Ciccullo A, Baldin G, Belmonti S, Moschese D, Lamonica S, Cauda R, Pezzotti P, Di Giambenedetto S.

Epidemiol Infect. 2019 Jan;147:e89. doi: 10.1017/S0950268819000098.

20.

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.

Rossetti B, Gagliardini R, Sterrantino G, Colangeli V, Latini A, Colafigli M, Vignale F, Rusconi S, Di Biagio A, Orofino G, Mezzaroma I, Vullo V, Francisci D, Mastroianni C, Trezzi M, Canovari B, Lamonica S, Ciccullo A, Borghetti A, DʼArminio Monforte A, Di Giambenedetto S, De Luca A; for GUSTA trial study group.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986. No abstract available.

21.

Liver fibrosis is associated with cognitive impairment in people living with HIV.

Ciccarelli N, Fabbiani M, Brita AC, De Marco R, Grima P, Gagliardini R, Borghetti A, Cauda R, Di Giambenedetto S.

Infection. 2019 Aug;47(4):589-593. doi: 10.1007/s15010-019-01284-8. Epub 2019 Feb 19.

PMID:
30784024
22.

Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice.

Baldin G, Ciccullo A, Borghetti A, Di Giambenedetto S.

J Antimicrob Chemother. 2019 May 1;74(5):1461-1463. doi: 10.1093/jac/dkz009. No abstract available.

PMID:
30726922
23.

Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.

Bavaro DF, Di Carlo D, Zuccalà P, Bai F, Incardona F, Battisti A, Giachè S, Salomoni E, Gagliardini R, Di Giambenedetto S, Pecorari M, Zazzi M, De Luca A, Bezenchek A, Lo Caputo S.

Infect Dis (Lond). 2019 Mar;51(3):234-239. doi: 10.1080/23744235.2018.1544423. Epub 2019 Jan 21. No abstract available.

PMID:
30663927
24.

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.

Borghetti A, Lombardi F, Gagliardini R, Baldin G, Ciccullo A, Moschese D, Emiliozzi A, Belmonti S, Lamonica S, Montagnani F, Visconti E, De Luca A, Di Giambenedetto S.

BMC Infect Dis. 2019 Jan 17;19(1):59. doi: 10.1186/s12879-018-3666-8.

25.

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV.

Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S.

J Antimicrob Chemother. 2019 Apr 1;74(4):1035-1043. doi: 10.1093/jac/dky508.

PMID:
30561642
26.

Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.

Ciccullo A, D'Avino A, Lassandro AP, Baldin G, Borghetti A, Dusina A, Emiliozzi A, Gagliardini R, Moschese D, Belmonti S, Lombardi F, Di Giambenedetto S.

Infez Med. 2018 Dec 1;26(4):336-340.

27.

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.

Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu MV, Giacomelli A, Lagi F, Latini A, Bagella P, De Luca A, Di Giambenedetto S, Madeddu G.

HIV Med. 2019 Feb;20(2):164-168. doi: 10.1111/hiv.12688. Epub 2018 Nov 20.

PMID:
30457197
28.

The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy.

Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sonnerborg A, Ruiz L, Monno L, Di Giambenedetto S, Gori A, Lapadula G; European Transmitted Drug Resistance collaboration (EU-TDR).

AIDS. 2019 Feb 1;33(2):315-326. doi: 10.1097/QAD.0000000000002046.

PMID:
30325769
29.

A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.

Ciccullo A, Baldin G, Capetti A, Rusconi S, Sterrantino G, d'Ettorre G, Colafigli M, Modica S, Lagi F, Giacomelli A, Cossu MV, Restelli S, De Luca A, Di Giambenedetto S.

Antivir Ther. 2019;24(1):63-67. doi: 10.3851/IMP3270.

PMID:
30277466
30.

Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.

Perez-Molina JA, Pulido F, Di Giambenedetto S, Ribera E, Moreno S, Zamora J, Coscia C, Alejos B, Pitch J, Gatell JM, De Luca A, Arribas JR.

J Antimicrob Chemother. 2018 Nov 1;73(11):2927-2935. doi: 10.1093/jac/dky299.

PMID:
30085184
31.

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.

Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A; ARCA Study Group .

Open Forum Infect Dis. 2018 May 15;5(6):ofy113. doi: 10.1093/ofid/ofy113. eCollection 2018 Jun.

32.

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016.

Rossetti B, Di Giambenedetto S, Torti C, Postorino MC, Punzi G, Saladini F, Gennari W, Borghi V, Monno L, Pignataro AR, Polilli E, Colafigli M, Poggi A, Tini S, Zazzi M, De Luca A; Antiviral Response Cohort Analysis (ARCA) Collaborative Group.

HIV Med. 2018 Oct;19(9):619-628. doi: 10.1111/hiv.12640. Epub 2018 Jun 22.

PMID:
29932313
33.

Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.

Belmonti S, Lombardi F, Quiros-Roldan E, Latini A, Castagna A, Borghetti A, Baldin G, Ciccullo A, Cauda R, De Luca A, Di Giambenedetto S; ATLAS-M Study Group.

J Antimicrob Chemother. 2018 Jul 1;73(7):1949-1954. doi: 10.1093/jac/dky125.

PMID:
29788156
34.

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.

Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group.

J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.

PMID:
29668978
35.

HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART.

Lombardi F, Belmonti S, Rapone L, Borghetti A, Ciccullo A, Gagliardini R, Baldin G, Montagnani F, Moschese D, Emiliozzi A, Rossetti B, De Luca A, Di Giambenedetto S.

J Clin Virol. 2018 Jun;103:57-62. doi: 10.1016/j.jcv.2018.03.013. Epub 2018 Apr 2.

PMID:
29656086
36.

Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication.

Borghetti A, Baldin G, Lombardi F, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Latini A, Cossu MV, Gagliardini R, De Luca A, Di Giambenedetto S.

HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12611. [Epub ahead of print]

PMID:
29573320
37.

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.

Capetti AF, Cossu MV, Sterrantino G, Barbarini G, Di Giambenedetto S, De Socio GV, Orofino G, Di Biagio A, Celesia BM, Rusconi S, Argenteri B, Rizzardini G.

Ann Pharmacother. 2018 Aug;52(8):740-746. doi: 10.1177/1060028018761600. Epub 2018 Feb 26.

PMID:
29482352
38.

An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy.

Ciccullo A, Gagliardini R, Baldin G, Borghetti A, Moschese D, Emiliozzi A, Lombardi F, Ricci R, Speziale D, Pallavicini F, Di Giambenedetto S.

HIV Med. 2018 Jul;19(6):369-375. doi: 10.1111/hiv.12597. Epub 2018 Jan 29.

PMID:
29380498
39.

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.

Rossetti B, Gagliardini R, Meini G, Sterrantino G, Colangeli V, Re MC, Latini A, Colafigli M, Vignale F, Rusconi S, Micheli V, Di Biagio A, Orofino G, Ghisetti V, Fantauzzi A, Vullo V, Grima P, Francisci D, Mastroianni C, Antinori A, Trezzi M, Lisi L, Navarra P, Canovari B, D'Arminio Monforte A, Lamonica S, D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A; for GUSTA trial study group.

PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017.

40.

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.

Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D.

Clinicoecon Outcomes Res. 2017 Sep 27;9:569-571. doi: 10.2147/CEOR.S143377. eCollection 2017. No abstract available.

41.

Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy.

Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M.

Clin Microbiol Infect. 2018 Mar;24(3):308.e5-308.e8. doi: 10.1016/j.cmi.2017.08.003. Epub 2017 Aug 12.

42.

3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.

Gagliardini R, Bandera A, Zaccarelli M, Sterrantino G, Latini A, D'Avino A, Lapadula G, Antinori A, Cauda R, De Luca A, Gori A, Di Giambenedetto S, Fabbiani M.

Antivir Ther. 2018;23(2):139-148. doi: 10.3851/IMP3188.

PMID:
28799920
43.

Morning dosing for dolutegravir-related insomnia and sleep disorders.

Capetti AF, Di Giambenedetto S, Latini A, Sterrantino G, De Benedetto I, Cossu MV, Gori A.

HIV Med. 2018 May;19(5):e62-e63. doi: 10.1111/hiv.12540. Epub 2017 Aug 1. No abstract available.

PMID:
28762661
44.

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group.

Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5.

PMID:
28477212
45.

Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.

Rossetti B, Meini G, Bianco C, Lamonica S, Mondi A, Belmonti S, Fanti I, Ciccarelli N, Di Giambenedetto S, Zazzi M, De Luca A.

J Clin Virol. 2017 Jun;91:18-24. doi: 10.1016/j.jcv.2017.03.018. Epub 2017 Mar 23.

PMID:
28395180
46.

Endocarditis sustained by Streptococcus viridans with normal levels of procalcitonin: an unexpected finding.

Merra G, Marsiliani D, Di Giambenedetto S, Franceschi F.

Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1281-1284.

47.

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.

Lombardi F, Belmonti S, Quiros-Roldan E, Latini A, Castagna A, D'Ettorre G, Gagliardini R, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S; AtLaS-M Study Group.

J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059. doi: 10.1093/jac/dkx068.

PMID:
28333353
48.
49.

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).

Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group.

J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

PMID:
28093483
50.

Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.

Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group.

AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. No abstract available.

PMID:
28079545

Supplemental Content

Loading ...
Support Center